Skip to main content
TipRanks
Go Ultimate75% OFF

Precision Optics Corporation (POCI) AI Stock Analysis

23 Followers
POCI

Precision Optics Corporation

(NASDAQ:POCI)

Select Model
Rating:46Neutral
Price Target:$4.00â–¼(-1.72% Downside)
Action:reiterated
Date:11/20/26

The overall score of 46 reflects a high-risk, early-stage company with significant near-term headwinds. The most significant factors are the weak financial performance, characterized by negative cash flow and unprofitability, and the bearish technical trend with the stock trading below all major moving averages. These are partially offset by a moderately positive earnings call outlook, where management detailed a credible recovery plan with multiple programs transitioning to production and reiterated annual guidance. The company's low-debt balance sheet provides a runway, but until revenue growth translates into positive earnings and cash flow, the stock remains under pressure.

Positive Factors
Revenue and Gross-Margin ImprovementImproving revenue, production volume, and gross margin indicate stronger execution and better absorption of manufacturing costs. If sustained across programs, these gains can support narrowing losses, improve operating leverage, and strengthen the economics of POCI’s specialized optical manufacturing platform.
Negative Factors
Persistent Losses and Cash ConsumptionPOCI remains dependent on funding while its operations consume cash and profitability is negative. Continued operating losses can limit investment capacity, weaken financial flexibility, and increase reliance on external capital unless revenue growth and manufacturing efficiency produce sustained operating leverage.

Precision Optics Corporation Key Performance Indicators (KPIs)

Revenue by SegmentBreaks down revenue by different business segments, highlighting which parts of the company are driving growth and profitability, and where there might be challenges or opportunities for expansion.

$0.00$1.00M$2.00M$3.00M$4.00M$5.00M$6.00MMar 21Jun 21Sep 21Dec 21Mar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25
Chart Insights

Precision Optics Corporation's Engineering Design Services segment experienced a significant revenue decline after a peak in early 2024, indicating potential challenges in maintaining client demand or project completions. Conversely, Optical Components show resilience with consistent growth, suggesting strong market demand or successful product innovations. The Medical Device Products & Assemblies segment is facing a downturn, possibly due to competitive pressures or market saturation. The absence of revenue from Systems Manufacturing and Technology Rights highlights a focus on core segments. Investors should watch for strategic pivots or new initiatives to drive growth.

Data provided by:The Fly

Precision Optics Corporation (POCI) vs. SPDR S&P 500 ETF (SPY)

-20%-10%0%10%20%30%40%POCI-9.35%SPY+8.20%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$44.75M
Dividend Yield
―
Average Volume (3M)
44.02K
Price to Earnings (P/E)
-13.7
Beta (1Y)
0.32
Revenue Growth
52.97%
EPS Growth
65.02%
Country
US
Employees
108
Sector
Healthcare
Sector Strength
51
Industry
Medical - Instruments & Supplies

Precision Optics Corporation Business Overview & Revenue Model

Company Description

Precision Optics Corporation, Inc. (POCI) specializes in the engineering, manufacturing, and sale of advanced optical and illumination systems, along with their complementary components. Its main operational regions are the United States and the Euro...

Precision Optics Corporation Earnings Call Summary

Earnings Call Date:Nov 16, 2026(Q1-2027)|% Change Since:-18.11%|Next Earnings Date:Nov 14, 2024
Earnings Call SentimentPositive

The call was broadly optimistic despite a near-term revenue and profitability dip caused by the established satellite customer’s demand pullback and the delayed production start for the second satellite program. Year-over-year revenue, gross margin, operating loss, net loss, and adjusted EBITDA all improved, while multiple medical, defense, aerospace, and satellite programs are progressing toward production. Management reiterated fiscal 2027 guidance and expects recovery in the second half, although Q2 is expected to be the weakest quarter and several market opportunities remain in development.

Positive Updates

Year-over-Year Revenue Growth
First-quarter fiscal 2027 revenue was $8.2 million, up 22% from $6.7 million a year ago, although it was down from the record $8.8 million in the prior quarter.

Negative Updates

Sequential Revenue Decline
First-quarter revenue of $8.2 million declined from the record $8.8 million in the fourth quarter of fiscal 2026, reflecting reduced satellite shipments.

Company Guidance

Management reiterated fiscal 2027 guidance for revenue of $30 million to $33 million and an adjusted EBITDA loss of $1.2 million to $1.7 million, expects the second quarter to be the weakest of the year with a substantial adjusted EBITDA loss larger than the loss in the first quarter, and expects satellite subassembly revenue of $1.2 million in Q2 and approximately $2 million for each of Q3 and Q4, with revenue on this program expected to recover in Q3 and Q4. The four programs transferring to production are expected to reach a combined annual run rate of $1.5 million to $2 million per year by the end of this fiscal year and eventually contribute approximately $5 million to $6 million annually; the micro arthroscope is expected to start at about $100,000 a quarter and could double or even triple from that level, while the ophthalmic program could double in the next couple of quarters. Ross revenue is anticipated to continue at $1.3 million for the remainder of fiscal 2027, quarterly revenue is expected to again reach new record highs beyond Q2, and the second satellite customer now anticipates production to begin about a year from now in the fourth quarter of calendar 2028.

Precision Optics Corporation Financial Statement Overview

Summary

Financial performance is weak. While TTM revenue growth is strong, profitability is a major concern with contracting gross margins (19% TTM) and persistent net losses. Cash flow is negative, with the company burning cash to fund operations. The balance sheet is stable with low debt, providing a cushion, but the inability to convert growth into positive earnings and cash generation is a significant risk.

Income Statement

28Negative

Balance Sheet

55Neutral

Cash Flow

35Negative
Financial statement breakdown
BreakdownTTMJun 2026Jun 2025Sep 2024Jun 2023Jun 2022
Income Statement
Total Revenue33.00M31.53M19.09M19.10M21.04M15.68M
Gross Profit6.32M5.43M3.40M5.80M7.73M4.93M
EBITDA-2.08M-3.20M-5.34M-2.51M286.99K-581.59K
Net Income-2.47M-3.63M-5.78M-2.95M-144.61K-928.42K
Balance Sheet
Total Assets30.62M32.34M19.79M16.91M19.74M16.70M
Cash, Cash Equivalents and Short-Term Investments8.97M9.84M1.77M405.28K2.93M605.75K
Total Debt3.83M4.06M2.04M3.43M3.16M3.00M
Total Liabilities10.42M11.99M7.53M6.84M7.69M7.73M
Stockholders Equity20.20M20.35M12.26M10.07M12.05M8.97M
Cash Flow
Free Cash Flow-2.51M-1.98M-3.77M-2.98M-133.59K-1.09M
Operating Cash Flow-2.30M-1.55M-3.55M-2.68M-81.09K-933.37K
Investing Cash Flow-175.59K-429.35K-233.47K-293.88K-52.50K-407.80K
Financing Cash Flow10.05M10.05M5.15M456.32K2.45M1.09M

Precision Optics Corporation Technical Analysis

Technical Analysis SentimentNegative
Last Price4.07

Price Trends

50DMA4.53Negative
100DMA4.49Negative
200DMA4.61Negative

Market Momentum

MACD-0.01Positive
RSI35.49Neutral
STOCH3.48Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For POCI, the sentiment is Negative. The current price of 4.07 is below the 20-day moving average (MA) of 4.68, below the 50-day MA of 4.53, and below the 200-day MA of 4.61, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 35.49 is Neutral, neither overbought nor oversold. The STOCH value of 3.48 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for POCI.

Precision Optics Corporation Risk Analysis

Precision Optics Corporation disclosed 32 risk factors in its most recent earnings report. Precision Optics Corporation reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

2 New Risks
1.Changes in U.S. Tariff Policy and Related Trade Actions Could Adversely Affect Our International Supply Chain, Costs, and Competitive PositionQ2, 2025
2.Changes in U.S. Tariff Policy and Related Trade Actions Could Adversely Affect Our International Supply Chain, Costs, and Competitive PositionQ1, 2025

Precision Optics Corporation Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

POCI against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
POCIPOCI46Neutral$44.75M-13.72-14.10%―52.97%65.02%
RVPRVP43Neutral$17.93M-2.85-8.48%―0.12%5.16%
MLSSMLSS42Neutral$21.93M-5.80-122.29%―3.93%48.18%
NXGLNXGL33Underperform$10.46M-0.22-151.60%―5.54%-98.10%
FEMYFEMY28Underperform$10.91M-0.32-114.48%―-4.21%78.58%

* Healthcare Sector Average

Performance Comparison

-50%0%50%POCIRVPMLSSFEMYNXGLDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
POCI and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
POCIPrecision Optics Corporation, Inc.4.07-0.53-11.52%
RVPRetractable Technologies0.60-0.22-26.95%
MLSSMilestone Scientific Inc0.24-0.07-21.94%
FEMYFemasys, Inc.1.26-17.12-93.15%
NXGLNexgel, Inc.3.35-28.25-89.40%

Precision Optics Corporation Corporate Events

Business Operations and StrategyRegulatory Filings and Compliance

Precision Optics Signs New Facility Lease Agreement

Positive
Oct 30, 2026

On October 28, 2026, Precision Optics Corporation, Inc. entered into a new lease agreement with Equity Assets, Inc. for its existing facility at 22-28 East Broadway in Gardner, Massachusetts, covering approximately 12,292 rentable square feet of comm...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 20, 2026